Astra enters the pan-KRAS game
A deal with Jacobio is worth $100m up front.
The conjugate enthusiasm bypasses Mythic
The private ADC company is being wound down.
Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Corcept tries to repeat the glucocorticoid trick
Nenocorilant features among the latest industry projects newly into phase 1.
Lung toxicity deaths halt ifinatamab
Ideate-Lung02 goes on global clinical hold.
